Sugi Predict

Sugi Predict / Compounds / SCHEMBL533759

SCHEMBL533759

SCHEMBL533759

CCCCCCCCCCCCCCCCCCCCCCOc1ccc(C(O)c2ccc(OCCCCCCCCCCCCCCCCCCCCCC)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR5A1 Q13285 1/20 0.65
▸ TP53 P04637 2/20 0.57
▸ TSHR P16473 1/20 0.57
▸ SLC2A1 P11166 1/20 0.57
▸ LMNA P02545 2/20 0.56
▸ MMP9 P14780 1/20 0.56
▸ MMP8 P22894 1/20 0.56
▸ MMP13 P45452 1/20 0.56
▸ LTA4H P09960 3/20 0.56
▸ PLA2G4B P0C869 2/20 0.56
▸ POLB P06746 1/20 0.54
▸ RARB P10826 3/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28983023 1.00 NR5A1 (0.65) NR5A1TP53TSHRSLC2A1LMNA
SCHEMBL13303326 0.94 LTA4H (0.55) NR5A1SLC2A1LMNAMMP9MMP8
SCHEMBL19415099 0.91 NR5A1 (0.67) NR5A1TP53TSHRSLC2A1LMNA
SCHEMBL11603837 0.89 NR5A1 (0.65) NR5A1TP53TSHRSLC2A1LMNA
SCHEMBL9808863 0.87 NR5A1 (0.62) NR5A1TP53TSHRSLC2A1LMNA
SCHEMBL9478810 0.87 NR5A1 (0.62) NR5A1TP53TSHRSLC2A1LMNA
SCHEMBL10333045 0.87 NR5A1 (0.62) NR5A1TP53TSHRSLC2A1LMNA
SCHEMBL9499075 0.86 NR5A1 (0.61) NR5A1TP53TSHRSLC2A1LMNA
SCHEMBL9500254 0.86 NR5A1 (0.61) NR5A1TP53TSHRSLC2A1LMNA
SCHEMBL9499161 0.86 NR5A1 (0.61) NR5A1TP53TSHRSLC2A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9670121-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2017-06-06 — — US claimed
US-9353148-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 — — US claimed
US-9353147-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 — — US claimed
US-20160060198-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2016-03-03 — — US claimed
US-9169187-B2 Method of making peptides using diphenylmethane compound AJINOMOTO CO., INC. (JP) 2015-10-27 — — US claimed
US-20140213761-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC (JP) 2014-07-31 — — US claimed
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-27 — — US claimed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US claimed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 — — EP claimed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US claimed
EP-4673424-A1 LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS Regeneron Pharmaceuticals, Inc. (US) 2026-01-07 — — EP disclosed
US-12351601-B2 Method for producing peptide continuously AJINOMOTO CO., INC. (JP) 2025-07-08 — — US disclosed
WO-2025122535-A2 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — WO disclosed
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — US disclosed
WO-2024182268-A1 LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS REGENERON PHARMACEUTICALS, INC. (US) 2024-09-06 — — WO disclosed
EP-2711370-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE Ajinomoto Co., Inc. (JP) 2014-03-26 — — EP disclosed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US disclosed
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2012-11-22 — — US disclosed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 — — EP disclosed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249374-A1 DIPHENYLMETHANE COMPOUND CCKAR, DNPEP, QPCTL NR5A1 2883/4885TP53 1289/4885TSHR 2188/4885
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS VIP, RNGTT, SSU72 NR5A1 1636/4885TP53 1843/4885TSHR 2281/4885
US-20140213761-A1 DIPHENYLMETHANE COMPOUND CCKAR, VIP, CCKBR NR5A1 3226/4885TP53 2202/4885TSHR 1541/4885
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE VIP, ANPEP, NPPA NR5A1 2972/4885TP53 867/4885TSHR 2603/4885
US-20160060198-A1 DIPHENYLMETHANE COMPOUND CCKAR, VIP, CCKBR NR5A1 3226/4885TP53 2202/4885TSHR 1541/4885
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE ANPEP, NPPA, LNPEP NR5A1 2104/4885TP53 793/4885TSHR 1168/4885
US-12351601-B2 Method for producing peptide continuously VIP, NPPA, NGLY1 NR5A1 2347/4885TP53 787/4885TSHR 1885/4885
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE RNGTT, POLM, RNMT NR5A1 2010/4885TP53 1957/4885TSHR 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.